Clinical trials: Hematological Patients
Hematological Diseases, Critical Illness
Assessment of Admission to the ICU of Onco-hematological Patients.
Multicenter, observational and prospective study.
- Trial name
- NCT06113601
- Testing
- There is no intervention.
- Volunteers
- 800 people
- Sponsor
- University Hospital A Coruña
Hematological Malignancy, Acute Respiratory Failure
Prognosis of Hematological Cancer Patient Underwent Mechanical Ventillation
This observational cohort aimed to re-evaluate the outcome of hematologic cancer patients admitted to the intensive care unit of Mansoura oncology center through a cohort study as regards their need for mechanical ventilation…
- Conditions
- Hematological Malignancy, Acute Respiratory Failure, Mechanical Ventilation
- Trial name
- NCT02562105
- Testing
- Mechanical ventilation
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Mansoura University
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
This study will assess the efficacy and safety of ibandronate (Bondronat), administered intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate to severe pain.
- Trial name
- NCT02561039
- Testing
- Ibandronate
- Where
- 9 sites in Bulgaria
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Acute Leukemia, Acute Myeloid Leukemia
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT02722668
- Testing
- Fludarabine, Cyclophosphamide, MMF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
T-cell Lymphoma, T-cell Leukemia
CD4CAR for CD4+ Leukemia and Lymphoma
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma.
- Trial name
- NCT03829540
- Testing
- CD4CAR
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Huda Salman
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Myeloproliferative Disorders, Leukemia
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00305682
- Testing
- anti-thymocyte globulin, cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Cancer, Ethics
Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies.
The decision to limit or withdraw specific therapies (DLWT) in patients with advanced cancer is a complex process that is always painful for patients, relatives and professionals.
- Trial name
- WHATELSE (NCT02841124)
- Testing
- interviews
- Where
- 5 sites in France
- Volunteers
- 21 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Advanced Solid Tumors and Hematological Malignancies
Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα and enhances the phagocytosis of cancer cells by macrophages.
- Trial name
- NCT04854681
- Testing
- TQB2928 Injection
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with…
- Trial name
- NCT06049667
- Testing
- NTQ2494 tablet
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory
- Trial name
- NCT04603872
- Testing
- CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Adapted Physical Activity, Hematological Malignancies
APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU
Adapted Physical Activity (APA) is accepted as an effective, recommended and beneficial supportive care for the health of people with cancer during the different phases of the disease.
- Conditions
- Adapted Physical Activity, Hematological Malignancies, Anxiety, Relaxation
- Trial name
- APAER_H (NCT05475600)
- Testing
- Classical APA group:, APA with Exergaming device, APA associated with biofeedback relaxation
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
Relapsed disease is the most common cause of death in children with hematological malignancies. Patients who fail high-intensity conventional chemotherapeutic regimens or relapse after stem cell transplantation have a poor…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Secondary AML, Myelodysplastic Syndrome (MDS)
- Trial name
- NCT00145613
- Testing
- Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
COVID19- Infection with SARS-CoV-2 Virus, SARS-CoV-2 Positive Patients
Impact of the Elevation Training Mask in CrossFit® Post-SARS-CoV-2 Infection.
Introduction: The Elevation Training Mask (ETM) could restore respiratory or hematological organic damages from the acute or post-infection phase of severe acute respiratory syndrome coronavirus 2 (SARSCoV2) because it would…
- Conditions
- COVID19- Infection with SARS-CoV-2 Virus, SARS-CoV-2 Positive Patients, COVID-19 Pulmonary Complications, SARS-CoV-2 Infection (Symptomatic)
- Trial name
- ETMEXCOVID (NCT06806124)
- Testing
- Elevation Training Mask
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Valladolid
Solid Tumors, Hematological Malignancies
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
This is a prospective, randomized, open-label, Phase I, crossover study to assess the effect of food on the bioavailability of AXL1717 including patients with advanced malignant tumors
- Trial name
- NCT01725555
- Testing
- Fasted treatment: AXL1717, Fed treatment: AXL1717
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Axelar AB
Hematological Malignancy
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
The purpose of the study is to evaluate the pharmacokinetics (PK), safety and tolerability of multiple doses of intravenous (IV) and oral isavuconazonium sulfate administered daily in pediatric patients.
- Trial name
- NCT03241550
- Testing
- isavuconazonium sulfate - intravenous, isavuconazonium sulfate - oral
- Where
- 16 sites in United States
- Volunteers
- 49 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Graft-versus-host-disease, Graft Versus Host Disease, Chronic
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) represents the only curative option for many patients diagnosed with various hematologic neoplasms.
- Conditions
- Graft-versus-host-disease, Graft Versus Host Disease, Chronic, Stem Cell Transplant Complications, Hematological Malignancy
- Trial name
- NCT06279585
- Testing
- Physical therapy
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- University of Seville
Hyperuricemia
Rasburicase (Fasturtec) Registration Trial
Primary: To compare the efficacy of Rasburicase versus allopurinol in controlling tumor lysis-related hyperuricemia in Chinese patients with leukemia or lymphoma.
- Trial name
- NCT00607152
- Testing
- Rasburicase, Allopurinol
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sanofi